Vaccines-COVID-19: Phase 1 Trial Results Of NIAID And Moderna New COVID-19 mRNA-1273 Vaccine Shows Promise In Older Adults
Source: Vaccines-COVID-19 Oct 01, 2020 4 years, 1 month, 2 weeks, 6 days, 11 hours, 2 minutes ago
Vaccines-COVID-19: The NIAID And Moderna Inc Phase 1 clinical trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.
.jpg)
The trial results were published in the
New England Journal of Medicine.
https://www.nejm.org/doi/10.1056/NEJMoa2028436
The new experimental vaccine, mRNA-1273, was co-developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health and Moderna, Inc. of Cambridge, Massachusetts.
The vaccine’s Phase 1 clinical trial began on March 16, 2020, and was expanded to enroll older adults about one month later. Older adults are more vulnerable to complications of COVID-19 and are an important population for vaccination. Understanding how the vaccine affects older adults is a critical part of measuring its safety and efficacy.
The clinical trial was conducted at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, Emory University in Atlanta, and NIAID's Vaccine Research Center (VRC) clinic at the NIH Clinical Center in Bethesda, Maryland.
Dr Julie Ledgerwood, D.O., deputy director and chief medical officer at the VRC, oversaw the study at the NIH site. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for this trial. This trial is supported by the Infectious Diseases Clinical Research Consortium (IDCRC) through NIAID.
It was reported that in its expansion to include older adults, the trial enrolled 40 healthy volunteers: 20 adults ages 56 to 70 years, and 20 adults ages 71 years and older. Ten volunteers in each age group received a lower dose of the vaccine (25 μg), and 10 volunteers in each age group received a higher dose (100 μg).
Subsequently after approximately one month, volunteers then received a second dose of the same vaccine at the same dosage. Throughout the study, volunteers attended clinic visits to track their responses to the vaccine and assess safety.
The study team overall found that the investigational vaccine was well-tolerated in this older age group.
However some volunteers experienced some transient adverse effects, including fever and fatigue after vaccination, the researchers found that they also exhibited a good immune response to the vaccine: the blood of vaccinated volunteers contained robust binding and neutralizing antibodies against SARS-CoV-2.
Significantly, the immune response to the vaccine seen in older volunteers was comparable to that seen in younger age groups.
The research study will continue to follow the older volunteers for approximately a year after second vaccination to monitor the long-term effects of the vaccine.
The study team accordingly said that these Phase 1 trial results further support testing of the investigational vaccine in older adults in an ongoing large Phase 3 trial.
For more on
gt;Vaccines-COVID-19, keep on logging to Thailand Medical News.
